| 上市公司 2025 | | | | 年半年度非经营性资金占用及其他关联资金往来情况汇总表 | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 编制单位：湖北亨迪药业股份有限公 | | | | | | | | | | | 司 | | | | | | | | 单位：人民币万元 | | | 资金占用方 | | | 占用方与上市公 | | 上市公司 | | 度占用累计 | 度占用资金 | | | 年度偿还 月 | 30 | 日占 | 占用形成 | | | | | | | | 非经营性资金占用 | | | | | 初占用 | | | | | | 资 | | | | | | 占用性质 | | | | | 名称 | | | 司的关联关系 | | 核算的会计科目 | | 发生金额 | 的利息 | 累计 | | 发生 | 用资金余 | | 原因 | | | | | | | | | | | | 金余额 | | | | | | | | | | | | （不含利息） | | （如有） | 金额 | 额 | | 控股股东、实际控制 ...

Fundraising Overview - The company raised a total of RMB 1,400,732,340.85 through its initial public offering, with the funds deposited in a designated account on December 16, 2021 [1] - As of June 30, 2025, the company has utilized RMB 573,704,200.00 of the raised funds, with RMB 46,799,400.00 used in the current year, all allocated to fundraising projects [1][2] - The remaining balance of the raised funds is RMB 935,461,000.00, which includes RMB 108,432,900.00 in net interest income after deducting fees [1] Fund Management - The company has established a fundraising management system to ensure compliance with regulatory requirements and protect investor interests, which was approved by the board on July 25, 2020 [1] - The company has signed a tripartite supervision agreement with its sponsor and a local bank to enhance the management and efficiency of the raised funds [1][2] Fund Usage and Adjustments - The company has reported that there are no fundraising projects that cannot be individually accounted for in terms of benefits [2] - The company has adjusted its fundraising usage plan, reallocating funds from the "annual production of 1,200 tons of raw materials project" to the "high-end pharmaceutical formulation internationalization project," with a total investment of RMB 33,227,000.00 planned for the latter [3][4] - The company has decided to terminate the "annual production of 5,000 tons of ibuprofen raw materials project" due to market saturation and price decline, reallocating the remaining funds to other projects [3][5] Project Progress and Timeline - The two fundraising projects, "annual production of 700 tons of raw materials project" and "annual production of 12 tons of anti-tumor raw materials project," are expected to reach usable status by December 2024, with ongoing construction and testing [3][5] - The "high-end pharmaceutical formulation internationalization project" is also facing delays, with an expected completion date extended to December 2026 due to regulatory and market factors [3][4]

亨迪药业2025半年报 ...

证券日报网讯 7月31日晚间，亨迪药业发布公告称，公司第二届监事会第十三次会议审议通过了《关于 对2025年半年度报告的审核意见的议案》等多项议案。 （文章来源：证券日报） ...

（文章来源：证券日报） 证券日报网讯 7月31日晚间，亨迪药业发布公告称，公司第二届董事会第十四次会议审议通过了《2025 年半年度募集资金存放与实际使用情况的专项报告》等多项议案。 ...

证券日报网讯7月31日晚间，亨迪药业（301211）发布公告称，公司将于2025年8月18日召开2025年第一 次临时股东大会。本次股东大会将审议《2025年半年度利润分配预案》等多项议案。 ...

Core Viewpoint - Hendi Pharmaceutical announced a profit distribution plan for the first half of 2025, proposing a stock dividend and a capital reserve increase for shareholders [2] Group 1: Profit Distribution Plan - The company plans to distribute cash dividends of 0 RMB per 10 shares (including tax) to all shareholders [2] - No bonus shares will be issued, with a proposal to increase capital reserves by 4.5 shares for every 10 shares held [2] - The proposal is subject to approval at the company's first extraordinary general meeting of shareholders in 2025 [2]

亨迪药业最新一期业绩显示，截至2025中报，公司营业总收入2.35亿元、同比减少2.93%，归属净利润 1854.71万元，同比减少72.92%，扣非净利润441.62万元，同比减少93.21%，流动比率14.794、速动比率 13.831、资产负债率5.66%。 天眼查商业履历信息显示，湖北亨迪药业股份有限公司，成立于1995年，位于荆门市，是一家以从事医 药制造业为主的企业。企业注册资本28800万人民币，实缴资本7020万人民币。公司法定代表人为程志 刚。 来源：金融界 金融界消息 截至2025年7月31日收盘，亨迪药业（301211）报收于19.44元，下跌0.21%，换手率 2.98%，成交量8.58万手，成交金额1.68亿元。 资金流向方面，今日主力资金净流出1103.20万元，占比成交额6.56%。其中，超大单净流出430.39万 元、占成交额2.56%，大单净流出672.81万元、占成交额4.0%，中单净流出流出370.36万元、占成交额 2.2%，小单净流入1473.55万元、占成交额8.76%。 通过天眼查大数据分析，湖北亨迪药业股份有限公司共对外投资了5家企业，参与招投标项目1685次， ...

经济观察网 7月31日，亨迪药业(301211.SZ)发布2025年半年度报告，该公司营业收入为2.35亿元，同比 减少2.93%。归属于上市公司股东的净利润为1854.71万元，同比减少72.92%。归属于上市公司股东的扣 除非经常性损益的净利润为441.62万元，同比减少93.21%。基本每股收益为0.06元。此外，拟向全体股 东向全体股东每10股转增4.5股。 ...

2024年1至12月份，亨迪药业的营业收入构成为：原料药占比79.88%，制剂占比19.11%，其他占比 1.01%。 （文章来源：每日经济新闻） 亨迪药业（SZ 301211，收盘价：19.44元）7月31日晚间发布公告称，公司第二届第十四次董事会会议 于2025年7月31日以现场和通讯方式召开。会议审议了《2025年半年度报告》等文件。 ...